ANI Pharmaceuticals, Inc. (ANIP) analyst actions
Rating and price-target actions on ANIP in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ANIP overview →
3 measured ANIP analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares | Press release | -0.25% | -2.83% | |
| ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences | Press release | +0.63% | -4.21% | |
| ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance | Press release | -5.10% | -2.79% |
Keep exploring
More ANIP: earnings → · SEC filings → · ANIP overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Teligent, Inc. (TLGT) | 502 | -0.17% | 43% |
| Zealand Pharma A/S - American Depositary Shares (ZEAL) | 501 | 0.00% | 40% |
| ARGOS THERAPEUTICS (ARGS) | 498 | -0.22% | 39% |
| BIOANALYTICAL SYSTEMS (BASI) | 498 | 0.00% | 40% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.